Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Scudla

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Neoplasma|January 27, 2010
The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myelomaV Scudla, T Pika, M Budikova, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 11, 2010
[18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods]M Myslivecek, J Bacovský, V Scudla, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|July 9, 2010
[Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, P Petrová, et al.
Casopis Lekaru Ceskych|February 28, 2007
[Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma]V Scudla, T Pika, M Budíková, et al.
Neoplasma|July 11, 2006
International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapyV Scudla, M Zemanova, J Minarik, et al.
Neoplasma|May 29, 2008
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myelomaM Zemanova, V Scudla, Z Adam, et al.
Neoplasma|August 18, 2015
Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categoriesT Pika, P Lochman, V Sandecka, et al.
Vnitrni Lekarstvi|September 7, 2004
[Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes]P Horák, Z Hermanová, M Ordeltová, et al.
Casopis Lekaru Ceskych|October 1, 2005
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]I Spicka, R Hájek, M Vytrasová, et al.
Neoplasma|January 1, 1989
Mediastinal teratoma and acute megakaryoblastic leukemiaV Mihál, J Dusek, M Jarosová, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Neoplasma|January 27, 2010
The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myelomaV Scudla, T Pika, M Budikova, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 11, 2010
[18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods]M Myslivecek, J Bacovský, V Scudla, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|July 9, 2010
[Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, P Petrová, et al.
Casopis Lekaru Ceskych|February 28, 2007
[Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma]V Scudla, T Pika, M Budíková, et al.
Neoplasma|July 11, 2006
International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapyV Scudla, M Zemanova, J Minarik, et al.
Neoplasma|May 29, 2008
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myelomaM Zemanova, V Scudla, Z Adam, et al.
Neoplasma|August 18, 2015
Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categoriesT Pika, P Lochman, V Sandecka, et al.
Vnitrni Lekarstvi|September 7, 2004
[Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes]P Horák, Z Hermanová, M Ordeltová, et al.
Casopis Lekaru Ceskych|October 1, 2005
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]I Spicka, R Hájek, M Vytrasová, et al.
Neoplasma|January 1, 1989
Mediastinal teratoma and acute megakaryoblastic leukemiaV Mihál, J Dusek, M Jarosová, et al.
Pageof 8